Oligomer-beta blocker conjugates
AssigneeNektar Therapeutics
InventorsJennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
Life of this patent
Estimating the term…
Abstract
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
Claims32
A compound comprising a beta blocker residue covalently attached via a stable or degradable linkage to a water-soluble, non-peptidic oligomer.
A composition comprising a compound comprising a beta blocker residue covalently attached via a stable or degradable linkage to a water-soluble and non-peptidic oligomer, and optionally, a pharmaceutically acceptable excipient.
A composition of matter comprising a compound comprising a beta blocker residue covalently attached via a stable or degradable linkage to a water-soluble, non-peptidic oligomer, wherein the compound is present in a dosage form.
A method comprising covalently attaching a water-soluble, non-peptidic oligomer to a beta blocker.
A method comprising administering a compound comprising a beta blocker residue covalently attached via a stable or degradable linkage to a water-soluble, non-peptidic oligomer.
Dependencies are inferred from the claim text.